Stockscreener 앱 받기
13.74
10.84%
-1.67
시간 외 거래:
13.64
-0.10
-0.73%
전일 마감가:
$15.41
열려 있는:
$15.22
하루 거래량:
240.51K
Relative Volume:
0.89
시가총액:
$398.73M
수익:
$66.59M
순이익/손실:
$-104.93M
주가수익비율:
-2.7758
EPS:
-4.95
순현금흐름:
$-96.48M
1주 성능:
-4.65%
1개월 성능:
+5.94%
6개월 성능:
+55.25%
1년 성능:
+93.52%
1일 변동 폭
$13.71
$15.48
1주일 범위
$13.71
$15.68
52주 변동 폭
$4.09
$17.15
Enanta Pharmaceuticals Inc Stock (ENTA) Company Profile
명칭
Enanta Pharmaceuticals Inc
전화
617 607 0800
주소
4 KINGSBURY AVENUE, WATERTOWN, MA
Compare ENTA vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ENTA
Enanta Pharmaceuticals Inc
|
13.74 | 447.19M | 66.59M | -104.93M | -96.48M | -4.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Enanta Pharmaceuticals Inc Stock (ENTA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-14 | 개시 | JP Morgan | Overweight |
| 2025-10-01 | 업그레이드 | Jefferies | Hold → Buy |
| 2025-07-28 | 재개 | H.C. Wainwright | Buy |
| 2023-08-09 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2023-08-08 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-12-09 | 개시 | H.C. Wainwright | Buy |
| 2022-07-06 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2022-06-01 | 업그레이드 | Evercore ISI | Underperform → In-line |
| 2021-10-07 | 개시 | Jefferies | Buy |
| 2021-09-09 | 개시 | SVB Leerink | Mkt Perform |
| 2021-01-29 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2020-11-24 | 개시 | Evercore ISI | Underperform |
| 2020-08-28 | 재개 | ROTH Capital | Buy |
| 2020-08-26 | 개시 | Piper Sandler | Overweight |
| 2020-07-27 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
| 2020-03-17 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2019-11-22 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-09-26 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2019-05-24 | 개시 | Wolfe Research | Outperform |
| 2019-04-23 | 업그레이드 | Berenberg | Hold → Buy |
| 2018-12-13 | 개시 | Berenberg | Hold |
| 2018-06-06 | 개시 | ROTH Capital | Buy |
| 2018-02-08 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2018-01-02 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2017-11-21 | 재확인 | RBC Capital Mkts | Outperform |
| 2017-09-15 | 개시 | RBC Capital Mkts | Outperform |
| 2017-07-11 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
| 2016-04-28 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2016-02-09 | 재확인 | Barclays | Underweight |
| 2015-10-23 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2015-10-23 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
모두보기
Enanta Pharmaceuticals Inc 주식(ENTA)의 최신 뉴스
Entry Recap: Why is Enanta Pharmaceuticals Inc stock going upJuly 2025 Opening Moves & Safe Capital Investment Plans - baoquankhu1.vn
Risk Analysis: How sensitive is Enanta Pharmaceuticals Inc to inflationEarnings Miss & AI Optimized Trade Strategies - baoquankhu1.vn
Enanta Pharmaceuticals to Present at The Citizens Life Sciences Conference - Yahoo Finance
Responsive Playbooks and the ENTA Inflection - Stock Traders Daily
Primary Biliary Cholangitis Market: Rapid Increment Driven by Innovation by 2034 – DelveInsight - StreetInsider
ENTA SEC FilingsEnanta Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Levels Update: Should I trade or invest in Enanta Pharmaceuticals Inc2025 Price Targets & Scalable Portfolio Growth Methods - baoquankhu1.vn
[EFFECT] ENANTA PHARMACEUTICALS INC SEC Filing - Stock Titan
ENTA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Can Enanta Pharmaceuticals Inc. reach all time highs this yearNew Guidance & High Accuracy Swing Entry Alerts - mfd.ru
Understanding the Setup: (ENTA) and Scalable Risk - Stock Traders Daily
Is Enanta Pharmaceuticals Inc. (9EP) stock included in top ETFsJuly 2025 Outlook & AI Powered Market Trend Analysis - mfd.ru
Analysts Set Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) PT at $20.33 - Defense World
Aug Decliners: Is Enanta Pharmaceuticals Inc backed by strong institutional buyingJuly 2025 Sentiment & Precise Swing Trade Entry Alerts - baoquankhu1.vn
ENTA PE Ratio & Valuation, Is ENTA Overvalued - Intellectia AI
Enanta Pharmaceuticals (ENTA) CSO nets PSU and rTSRU share awards - Stock Titan
Can Enanta Pharmaceuticals Inc. (9EP) stock surprise with quarterly resultsTrade Analysis Summary & Long-Term Growth Portfolio Plans - mfd.ru
What Makes Enanta Pharmaceuticals (ENTA) a New Buy Stock - Yahoo Finance
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Equities Analysts Issue Forecasts for ENTA Q2 Earnings - MarketBeat
Analysts Are Updating Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Estimates After Its First-Quarter Results - simplywall.st
The Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) First-Quarter Results Are Out And Analysts Have Published New Forecasts - 富途牛牛
Enanta (ENTA) Announces $150 Million Mixed Securities Shelf Registration - GuruFocus
Enanta Pharmaceuticals (ENTA) Quarterly Loss Narrows Yet Keeps Profitability Concerns In Investor Focus - Sahm
Enanta Pharmaceuticals to Present Preclinical Data for EDP-978, its KIT Inhibitor in Development for - PharmiWeb.com
Enanta Pharmaceuticals to Present Preclinical Data for EDP-978, its KIT Inhibitor in Development for the Treatment of Type 2 Immune Diseases, at the 2026 AAAAI Annual Meeting - BioSpace
Enanta Pharma (ENTA): Analyst Reiterates Buy Rating with $20 PT - GuruFocus
HC Wainwright Reaffirms "Buy" Rating for Enanta Pharmaceuticals (NASDAQ:ENTA) - MarketBeat
Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2025 - BioSpace
Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 202 - PharmiWeb.com
Enanta Pharmaceuticals (ENTA) Reports Strong Q1 Revenue and Fina - GuruFocus
Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Enanta Pharmaceuticals (NASDAQ:ENTA) Posts Earnings Results, Beats Estimates By $0.12 EPS - MarketBeat
Enanta Pharmaceuticals: Fiscal Q1 Earnings Snapshot - KVUE
Enanta Pharmaceuticals: Overview of Fiscal First Quarter Earnings - Bitget
Enanta Pharma Earnings Review: Q1 Summary - Benzinga
The Technical Signals Behind (ENTA) That Institutions Follow - Stock Traders Daily
Earnings Preview For Enanta Pharma - Sahm
Primary Biliary Cholangitis Market: Rapid Increment Driven by Innovation by 2034 – DelveInsight | Intercept Pharma, Enanta Pharma, COUR Pharma, Novartis, Gannex Pharma, Nanjing Chia-tai Tianqing Pharm - Barchart.com
Enanta Pharmaceuticals (ENTA) Projected to Post Quarterly Earnings on Monday - MarketBeat
Rate Hike: Does Enanta Pharmaceuticals Inc have consistent dividend growthPortfolio Performance Report & Fast Exit Strategy with Risk Control - baoquankhu1.vn
Insider Sell: What are Asset Entities Incs technical support levelsMarket Trend Report & High Accuracy Trade Alerts - baoquankhu1.vn
Precision Trading with Enanta Pharmaceuticals Inc. (ENTA) Risk Zones - Stock Traders Daily
Enanta (NASDAQ: ENTA) seeks 1.6M-share boost to 2019 equity plan - Stock Titan
CEO Moves: Why is Enanta Pharmaceuticals Inc stock going up2025 Market WrapUp & AI Optimized Trading Strategy Guides - baoquankhu1.vn
Sentiment Review: What are Enanta Pharmaceuticals Inc.’s technical support levelsDividend Hike & Low Risk High Reward Trade Ideas - baoquankhu1.vn
Guidance Update: Why is SWKH stock going downSwing Trade & Verified Short-Term Plans - baoquankhu1.vn
Enanta Pharmaceuticals to Present at the Wells Fargo Securities 2013 Healthcare Conference - AOL.com
Why Enanta Pharmaceuticals Inc. stock appeals to analystsJobs Report & Free Long-Term Investment Growth Plans - bollywoodhelpline.com
Technical Reactions to ENTA Trends in Macro Strategies - Stock Traders Daily
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Enanta Pharmaceuticals Inc (ENTA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.69%
0.68%
자본화:
|
볼륨(24시간):